## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `ss-31-neuropathy`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/ss-31-neuropathy/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ss-31-neuropathy/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/ss-31-neuropathy/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/ss-31-neuropathy/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/ss-31-neuropathy/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/ss-31-neuropathy/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `ss-31-neuropathy` v2 · content_hash `ea9df679c4131e4b…` · thread_head genesis · 18 DIVs
- **thesis (c1):** SS-31 binds cardiolipin to stabilize inner mitochondrial membrane and reduce ROS.
  - c2 [human/active] Phase II randomized trial of topical elamipretide in 12 LHON patients assessed safety and visual outcomes over 52 weeks.
  - c5 [human/active] No large human trials exist for common peripheral neuropathies such as diabetic neuropathy.
  - c3 [preclinical/active] In LPS mouse model, SS-31 reversed hippocampal mitochondrial dysfunction, lowered ROS and inflammation, preserved synapses, and improved memory tests.
  - c4 [anecdotal/active] Reddit users with CFS/long COVID report subjective energy, cognitive, and one case of sensory nerve improvement after SS-31.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/ss-31-neuropathy/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/ss-31-neuropathy/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `ss-31-neuropathy`
- **title:** SS-31 (Elamipretide) for Neuropathy: Mitochondrial Repair Evidence
- **url:** https://miscsubjects.com/a/ss-31-neuropathy
- **register:** source_ledger
- **updated:** 2026-07-17T02:42:06.466Z
- **tags:** peptide, matrix

## Body

## What's breaking down

Neuropathy often stems from mitochondrial dysfunction inside neurons. Damaged mitochondria leak reactive oxygen species, impair ATP production, and trigger cell death or poor signaling along nerves. This creates a repair deficit where breakdown outruns regeneration. Oxidative stress and inflammation compound the issue in many cases, whether from metabolic stress, injury, or genetic mitochondrial defects. The result is persistent nerve signaling problems rather than simple symptom masking.

## Why SS-31 (Elamipretide) might help you

If mitochondrial cardiolipin instability sits at the root of your nerve energy failure, SS-31 (Elamipretide) is discussed because it binds cardiolipin in the inner mitochondrial membrane. This stabilizes the membrane, supports electron transport chain efficiency, and lowers excess ROS production. Therefore for you: If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain. The logic chain runs: mitochondrial stabilization → better ATP output in neurons → reduced oxidative damage → support for nerve maintenance pathways.

## How these fit together

Single-compound focus. SS-31 (Elamipretide) maps directly to the mitochondrial layer of degeneration. No sibling peptides in scope here.

## What the evidence actually shows

Human data exist for one specific mitochondrial optic neuropathy. A phase II randomized, double-masked, vehicle-controlled trial tested topical elamipretide in 12 patients with Leber hereditary optic neuropathy (LHON, m.11778G>A mutation). The study ran 52 weeks double-masked followed by open-label extension. It assessed safety, tolerability, and potential efficacy on visual function (human tier). Preclinical mouse work showed clearer mitochondrial rescue: LPS-induced systemic inflammation caused hippocampal mitochondrial membrane potential drop, ATP loss, ROS rise, and memory deficits; SS-31 treatment reversed these markers, reduced apoptosis, preserved dendritic spines, and improved behavioral tests (preclinical tier). Rat spinal cord injury models have explored similar mitochondrial protection with behavioral readouts, but results vary across studies (preclinical tier). No large human trials address common peripheral neuropathy forms such as diabetic or idiopathic cases.

## What scientists say

Researchers note SS-31's selective cardiolipin interaction improves bioenergetics and curbs apoptosis in mitochondrial disease models. They highlight its blood-brain barrier penetration in some contexts and call for more human neuropathy-specific work beyond rare optic forms. LHON trial authors emphasize safety in humans while noting efficacy signals remain preliminary (mechanistic and human tiers).

## What people say on Reddit

Anecdotal reports from users with chronic fatigue or long COVID describe subjective energy gains and cognitive clarity after SS-31 use. One user reported regained toe sensation after years of numbness and attributed it to nerve-level repair (anecdotal tier). Others note no benefit or stress that the compound remains investigational. These accounts come from self-experimentation threads and lack controlled verification.

## What people say on X

Limited public discussion appears on X. Mentions stay general, focusing on mitochondrial support in aging or rare disease contexts rather than neuropathy anecdotes. No high-visibility verified user reports surface in recent searches.

## What we do not know

Direct human evidence for common peripheral neuropathies is absent. Long-term nerve regeneration outcomes remain untested in controlled settings. Dose-response relationships, optimal duration, and combination effects with other interventions lack published data. Whether benefits persist after stopping treatment is unknown.

## Safety and limits

Human trials report good tolerability in mitochondrial disease populations, including Barth syndrome and primary mitochondrial myopathy studies (human tier). Topical LHON use showed acceptable local safety. Animal work flags no major acute toxicity at tested doses. Because human neuropathy data are sparse outside rare optic cases, any application stays exploratory. Regulatory status remains investigational for most indications.

## Claims (5)

- **c2** [human w=0.8] Phase II randomized trial of topical elamipretide in 12 LHON patients assessed safety and visual outcomes over 52 weeks.
  - who_claims: grok/grok-4.3
  - sources: s2
- **c5** [human w=0.8] No large human trials exist for common peripheral neuropathies such as diabetic neuropathy.
  - who_claims: grok/grok-4.3
- **c3** [preclinical w=0.5] In LPS mouse model, SS-31 reversed hippocampal mitochondrial dysfunction, lowered ROS and inflammation, preserved synapses, and improved memory tests.
  - who_claims: grok/grok-4.3
  - sources: s3
- **c1** [mechanistic w=0.3] SS-31 binds cardiolipin to stabilize inner mitochondrial membrane and reduce ROS.
  - who_claims: grok/grok-4.3
  - sources: s1
- **c4** [anecdotal w=0.3] Reddit users with CFS/long COVID report subjective energy, cognitive, and one case of sensory nerve improvement after SS-31.
  - who_claims: grok/grok-4.3
  - sources: s4

## Voxel graph (5 atoms · 9 edges)
- full graph: https://miscsubjects.com/api/articles/ss-31-neuropathy/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (4)
- chain valid: yes · head: `2cd73f80fe459e36`

### s1 · review · ok
- title: SS-31 (Elamipretide) — Peptide Evidence Score
- url: https://biomeme.com/applications/wellness/peptide-evidence/ss-31/
- summary: Mechanism summary from evidence framework page.
- quote: SS-31 selectively targets and stabilizes cardiolipin in the inner mitochondrial membrane... improves mitochondrial bioenergetics, reduces electron leak and ROS production
- claim_ids: c1
- hash: `d42598e176ddffe3`

### s2 · pubmed · ok
- title: Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial
- url: https://pubmed.ncbi.nlm.nih.gov/37923251/
- summary: Phase II human trial details for LHON.
- quote: This study aimed to assess the safety, tolerability, and potential efficacy of topical elamipretide in patients affected with Leber hereditary optic neuropathy (LHON).
- claim_ids: c2
- hash: `b689dbe517c13c8e`

### s3 · pubmed · ok
- title: Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice
- url: https://pubmed.ncbi.nlm.nih.gov/31747905/
- summary: Mouse study abstract detailing mitochondrial and behavioral outcomes.
- quote: These findings indicate that LPS-induced memory impairment can be attenuated by the mitochondrion-targeted antioxidant elamipretide.
- claim_ids: c3
- hash: `61137f50721f64d0`

### s4 · reddit · ok
- title: My Experience Treating my ME/CFS with mitochondrial peptide SS-31
- url: https://www.reddit.com/r/cfs/comments/1j2upcm/my_experience_treating_my_mecfs_with/
- summary: User anecdote on sensory recovery.
- quote: I can wiggle my toes in bed and feel them now. Ten years later! I 100% believe this is from the SS-31.
- claim_ids: c4
- hash: `2cd73f80fe459e36`

## Provenance (2 model passes)
- chain valid: yes · head: `6c346e5bea7e9486`

- write · grok/grok-4.3 · 2026-06-29T23:51 · hash `343e1b875b0d`
- voxel_divide · owner · 2026-07-17T02:42 · hash `6c346e5bea7e`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/ss-31-neuropathy/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/ss-31-neuropathy/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"ss-31-neuropathy","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest ss-31-neuropathy|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim ss-31-neuropathy|tier|assertion`
- **iMessage ask:** `ss-31-neuropathy|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `ss-31-neuropathy`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ss-31-neuropathy/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/ss-31-neuropathy/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*